Comparative Pharmacology of Antipsychotics Possessing Combined Dopamine D2 and Serotonin 5-HT1A Receptor Properties

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2011 Mar 12

PMID 21394633

Citations 52

Authors

Adrian Newman-Tancredi

Mark S Kleven

Affiliations

Soon will be listed here.

Abstract

Rationale: There is increasing interest in antipsychotics intended to manage positive symptoms via D(2) receptor blockade and improve negative symptoms and cognitive deficits via 5-HT(1A) activation. Such a strategy reduces side-effects such as the extrapyramidal syndrome (EPS), weight gain, and autonomic disturbance liability.

Objective: This study aims to review pharmacological literature on compounds interacting at both 5-HT(1A) and D(2) receptors (as well as at other receptors), including aripiprazole, perospirone, ziprasidone, bifeprunox, lurasidone and cariprazine, PF-217830, adoprazine, SSR181507, and F15063.

Methods: We examine data on in vitro binding and agonism and in vivo tests related to (1) positive symptoms (e.g., psychostimulant-induced hyperactivity or prepulse inhibition deficit), (2) negative symptoms (e.g., phencyclidine-induced social interaction deficits and cortical dopamine release), and (3) cognitive deficits (e.g., phencyclidine or scopolamine-induced memory deficits). EPS liability is assessed by measuring catalepsy and neuroendocrine impact by determining plasma prolactin, glucose, and corticosterone levels.

Results: Compounds possessing "balanced" 5-HT(1A) receptor agonism and D(2) antagonism (or weak partial agonism) and, in some cases, combined with other beneficial properties, such as 5-HT(2A) receptor antagonism, are efficacious in a broad range of rodent pharmacological models yet have a lower propensity to elicit EPS or metabolic dysfunction.

Conclusions: Recent compounds exhibiting combined 5-HT(1A)/D(2) properties may be effective in treating a broader range of symptoms of schizophrenia and be better tolerated than existing antipsychotics. Nevertheless, further investigations are necessary to evaluate recent compounds, notably in view of their differing levels of 5-HT(1A) affinity and efficacy, which can markedly influence activity and side-effect profiles.

Citing Articles

Compound PZ-1262, a 4-isoquinoline-sulfonamide analog of Brexpiprazole, produces potential antidepressant, anxiolytic and procognitive effects in rodent models.

Partyka A, Golebiowska J, Marciniec K, Canale V, Trybala W, Satala G Pharmacol Rep. 2025; .

PMID: 40064751 DOI: 10.1007/s43440-025-00713-w.

Augmentation therapy with serotonin receptor partial agonists on neurocognitive function in schizophrenia: A systematic review and meta-analysis.

Yamada R, Wada A, Stickley A, Yokoi Y, Sumiyoshi T Schizophr Res Cogn. 2023; 34:100290.

PMID: 37732133 PMC: 10507645. DOI: 10.1016/j.scog.2023.100290.

In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics.

Agren R, Betari N, Saarinen M, Zeberg H, Svenningsson P, Sahlholm K Int J Neuropsychopharmacol. 2023; 26(9):599-606.

PMID: 37549917 PMC: 10519813. DOI: 10.1093/ijnp/pyad049.

Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia.

Meyer J, Correll C CNS Drugs. 2023; 37(7):545-570.

PMID: 37470979 PMC: 10374807. DOI: 10.1007/s40263-023-01022-7.

Seasonality of brain function: role in psychiatric disorders.

Zhang R, Volkow N Transl Psychiatry. 2023; 13(1):65.

PMID: 36813773 PMC: 9947162. DOI: 10.1038/s41398-023-02365-x.

References

Cosi C, Carilla-Durand E, Assie M, Ormiere A, Maraval M, Leduc N . Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol. 2006; 535(1-3):135-44. DOI: 10.1016/j.ejphar.2006.01.051. View

Sumiyoshi T, Higuchi Y, Matsui M, Arai H, Takamiya C, Meltzer H . Effective adjunctive use of tandospirone with perospirone for enhancing verbal memory and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(4):965-7. DOI: 10.1016/j.pnpbp.2007.02.017. View

Mailman R, Murthy V . Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?. Curr Pharm Des. 2009; 16(5):488-501. PMC: 2958217. DOI: 10.2174/138161210790361461. View

Lieberman J, Kane J, Alvir J . Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl). 1987; 91(4):415-33. DOI: 10.1007/BF00216006. View

Lemonde S, Turecki G, Bakish D, Du L, Hrdina P, Bown C . Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci. 2003; 23(25):8788-99. PMC: 6740417. View

Li Z, Huang M, Ichikawa J, Dai J, Meltzer H . N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology. 2005; 30(11):1986-95. DOI: 10.1038/sj.npp.1300768. View

Gogos A, Nathan P, Guille V, Croft R, van den Buuse M . Estrogen prevents 5-HT1A receptor-induced disruptions of prepulse inhibition in healthy women. Neuropsychopharmacology. 2005; 31(4):885-9. DOI: 10.1038/sj.npp.1300933. View

Jones C, McCreary A . Serotonergic approaches in the development of novel antipsychotics. Neuropharmacology. 2008; 55(6):1056-65. DOI: 10.1016/j.neuropharm.2008.05.025. View

Auclair A, Kleven M, Barret-Grevoz C, Barreto M, Newman-Tancredi A, Depoortere R . Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys. Behav Brain Res. 2009; 203(2):288-95. DOI: 10.1016/j.bbr.2009.05.015. View

10.

Kuroki T, Nagao N, Nakahara T . Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res. 2008; 172:199-212. DOI: 10.1016/S0079-6123(08)00910-2. View

11.

Grunder G . Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Curr Opin Investig Drugs. 2010; 11(7):823-32. View

12.

Medori R, Mannaert E, Grunder G . Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur Neuropsychopharmacol. 2005; 16(4):233-40. DOI: 10.1016/j.euroneuro.2005.10.006. View

13.

Chou Y, Halldin C, Farde L . Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study. Psychopharmacology (Berl). 2003; 166(3):234-40. DOI: 10.1007/s00213-002-1256-2. View

14.

Stark A, Jordan S, Allers K, Bertekap R, Chen R, Mistry Kannan T . Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl). 2007; 190(3):373-82. DOI: 10.1007/s00213-006-0621-y. View

15.

Abi-Dargham A . Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol. 2004; 7 Suppl 1:S1-5. DOI: 10.1017/S1461145704004110. View

16.

Abdul-Monim Z, Reynolds G, Neill J . The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. J Psychopharmacol. 2003; 17(1):57-65. DOI: 10.1177/0269881103017001700. View

17.

Titier K, Girodet P, Verdoux H, Molimard M, Begaud B, Haverkamp W . Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death. Drug Saf. 2005; 28(1):35-51. DOI: 10.2165/00002018-200528010-00003. View

18.

Krystal J, DSouza D, Mathalon D, Perry E, Belger A, Hoffman R . NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl). 2003; 169(3-4):215-33. DOI: 10.1007/s00213-003-1582-z. View

19.

Burnet P, Eastwood S, Harrison P . [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int. 1997; 30(6):565-74. DOI: 10.1016/s0197-0186(96)00124-6. View

20.

McCormick P, Kapur S, Graff-Guerrero A, Raymond R, Nobrega J, Wilson A . The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro. Neuropsychopharmacology. 2010; 35(8):1826-35. PMC: 3055486. DOI: 10.1038/npp.2010.50. View